Free tool
FAERS Monitor: Empliciti
Last checked: Nov 20, 2026FDA FAERS (openFDA) last updated: Oct 28, 2026Methods & limitations
Reports naming BLA 761035 or its brand name (Empliciti, Elotuzumab). Reports on generic versions are filed under their own applications.
Reports
5,171
Serious
4,210
81% of reports
Hospitalization
2,018
Death reported
920
Any cause; not necessarily from the drug
Most reported reactions
MedDRA preferred terms.
- plasma cell myeloma576
- pneumonia304
- death298
- malignant neoplasm progression254
- fatigue236
- diarrhoea231
- pyrexia221
- drug ineffective204
- neutropenia194
- anaemia173
- thrombocytopenia146
- off label use142
- platelet count decreased134
- sepsis124
- neuropathy peripheral115
Reports by year received
View as table
| Year | Reports |
|---|---|
| 2010 | 2 |
| 2011 | 8 |
| 2012 | 41 |
| 2013 | 110 |
| 2014 | 102 |
| 2015 | 120 |
| 2016 | 495 |
| 2017 | 691 |
| 2018 | 598 |
| 2019 | 622 |
| 2020 | 629 |
| 2021 | 566 |
| 2022 | 392 |
| 2023 | 283 |
| 2024 | 190 |
| 2025 | 207 |
| 2026 | 115 |
Disproportionality screen
Proportional reporting ratio (PRR): how much more often each reaction appears in this drug's reports than in the other 21,048,988 FAERS reports. Flagged when PRR is at least 2, chi-squared at least 4 and there are 3 or more reports (Evans criteria). A screening statistic only.
| Reaction | Reports | PRR | 95% CI lower | Chi-squared |
|---|---|---|---|---|
| plasma cell myelomaSignal | 576 | 60.9 | 56.4 | 33,457 |
| malignant neoplasm progressionSignal | 254 | 10.1 | 9.0 | 2,081 |
| neutropeniaSignal | 194 | 5.8 | 5.1 | 772 |
| thrombocytopeniaSignal | 146 | 5.3 | 4.5 | 509 |
| platelet count decreasedSignal | 134 | 5.1 | 4.3 | 442 |
| neuropathy peripheralSignal | 115 | 4.9 | 4.1 | 357 |
| sepsisSignal | 124 | 4.5 | 3.8 | 338 |
| pneumoniaSignal | 304 | 3.8 | 3.4 | 640 |
| anaemiaSignal | 173 | 3.7 | 3.2 | 340 |
| pyrexiaSignal | 221 | 2.6 | 2.3 | 219 |
| diarrhoea | 231 | 1.5 | 1.3 | 34 |
| death | 298 | 1.4 | 1.3 | 36 |
| fatigue | 236 | 1.2 | 1.1 | 11 |
| off label use | 142 | 0.7 | 0.6 | 26 |
| drug ineffective | 204 | 0.6 | 0.6 | 47 |
A high PRR for a reaction that is also the condition being treated (for example "disease progression" for a cancer drug) is expected and is not a safety signal.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.